New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 14, 2012
09:25 EDTBV, BBY, CYTX, ALXA, ZQK, ADBEOn The Fly: Pre-market Movers
HIGHER AFTER EARNINGS: Adobe (ADBE), up 5.7%... ALSO HIGHER: Alexa Pharmaceuticals (ALXA), up 21.4% after approval granted in EU for Adasuve... Bazaarvoice (BV), up 7.4% after upgrade to Outperform at Credit Suisse... LOWER AFTER EARNINGS: Quiksilver (ZQK), down 14%... Verifone (PAY), down 7.6%... ALSO LOWER: Best Buy (BBY), down 10.8% after board extends deadline for bid from founder Schulze... Cytori Therapeutics (CYTX), down 15% after 7M share secondary stock offering.
News For BBY;ADBE;ALXA;BV;ZQK;CYTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2015
10:13 EDTBBYOptions with increasing implied volatility
Options with increasing implied volatility: ESPR SRPT CX RAX YY SPLK QIHU HFC OWW BBY
09:01 EDTBBYAmerican Express, Best Buy announce e-commerce technology integration
Subscribe for More Information
08:14 EDTCYTXCytori Therapeutics says company-supported trial in Japan to begin enrollment
Subscribe for More Information
July 29, 2015
10:41 EDTBBYOptions with increasing implied volatility
Subscribe for More Information
10:27 EDTBBYOptions with decreasing implied volatility
Subscribe for More Information
July 28, 2015
09:18 EDTCYTXOn The Fly: Pre-market Movers
Subscribe for More Information
08:10 EDTCYTXCytori licensee Kerastem receives conditional FDA approval for alopecia trial
Cytori Therapeutics announced that Kerastem Technologies, a wholly owned subsidiary of Bimini Technologies, received U.S. FDA conditional Investigational Device Exemption approval to conduct a clinical trial studying the safety and feasibility of its technology for the treatment of female and early male pattern baldness.The phase II study, known as the STYLE trial, follows initial clinical work in Europe and Japan. This clinical experience served as a basis for the FDA IDE submission. The data will be presented in September at the 2015 International Society of Hair Restoration Surgery meeting in Chicago. STYLE is a 70 patient controlled trial that is expected to begin enrollment in late 2015 at up to eight centers within the United States. The primary endpoint is safety and tolerability of the treatment and secondary endpoints include change in hair growth and density. In 2013, Bimini, a private medical technology company, acquired global and exclusive rights to commercialize Cytori Celution Technology for alopecia and hair related indications. Under the commercial agreement, Bimini will be responsible for all key activities including clinical studies, regulatory approvals, and market development. Bimini will acquire Cytori products at agreed upon transfer pricing and pay Cytori a perpetual royalty on sales.
July 27, 2015
06:05 EDTBBYBest Buy to begin selling Apple Watch in August, WSJ reports
Subscribe for More Information
July 23, 2015
19:24 EDTBBYWal-Mart's Apple Pay competitor launching soon, Bloomberg says
CurrentC, the mobile payment application funded by Wal-Mart (WMT), Target (TGT), Best Buy (BBY) and others, will see an early trial run next month, Bloomberg reported earlier, citing three people familiar with the situation. A spokesperson for Lowe's (LOW) said the consortium behind the app expects an official launch in Q3, and Bloomberg noted that CurrentC will compete with more "established" offerings such as Apple's (AAPL) Apple Pay and Google's (GOOG) Android Pay. Reference Link
July 20, 2015
09:31 EDTBBYBest Buy store rationalization to be catalyst, says BB&T
Subscribe for More Information
09:02 EDTADBEAdobe names Abhay Parasnis as CTO, senior VP of Platform Technology & Services
Adobe named Abhay Parasnis as chief technology officer and senior vice president of platform technology and services. Parasnis will drive Adobe’s technology strategy, architecture and innovation roadmap for its cloud services, focusing on integration of its three cloud services; providing a consistent customer experience via the cloud; and enabling the company’s cloud-based go-to-market strategies. Parasnis brings nearly 20 years of experience in the software industry. Most recently, he was president and chief operating officer of venture-funded enterprise mobility leader Kony.
July 17, 2015
16:24 EDTBBYOn The Fly: Top stock stories for Friday
Subscribe for More Information
12:38 EDTBBYOn The Fly: Top stock stories at midday
Subscribe for More Information
10:46 EDTBBYBest Buy sinks after analyst says sell to avoid comp sales risk
Subscribe for More Information
10:13 EDTBBYAmbarella to get boost from drone demand, analyst says
Ambarella (AMBA) should benefit from stronger than expected demand for drones, which are "literally flying off the shelves" at Best Buy (BBY), research firm Pacific Crest wrote in a note to investors today. Ambarella develops processors used in high definition cameras, such as those often utilized by drones. WHAT'S NEW: After conducting checks, Pacific Crest analyst Brad Erickson wrote that sales of drones have been stronger than expected. Ambarella should benefit from that trend, as well as from the fact that demand for GoPro (GPRO) cameras, which utilize Ambarella's chips, has been steady, Erickson stated. Although initial demand for GoPro's new Session camera "appears lukewarm," its newer cameras should drive a significant increase in sales volume starting in GoPro's October quarter, according to Erickson, who said the popularity of GoPro's cameras should enable Ambarella's results to beat Street expectations. The analyst continues to recommend buying Ambarella's stock and kept a $123 price target on the shares. WHAT'S NOTABLE: In a note to investors yesterday, Piper Jaffray analyst Erinn Murphy wrote that GoPro's risk/reward ratio was favorable heading into the company's Q2 results. According to Murphy, the stock fell recently because money rotated out of the shares following the initial public offering of Fitbit (FIT) and Goldman Sachs' initiation of coverage of the stock with a Neutral rating. However, Amazon (AMZN) data shows that GoPro's cameras are selling well and Ambarella's Q2 results beat expectations, Murphy noted. As a result, she expects GoPro's Q2 results to exceed expectations when they are reported next week. Murphy reiterated a $68 price target and Overweight rating on GoPro shares. PRICE ACTION: In early trading, Ambarella rose 1.3% to $109.59, while GoPro added 0.5% to $55.53.
10:05 EDTBBYOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Accretive Health (ACHI) downgraded to Market Perform from Outperform at Cowen... Allergan (AGN) downgraded to Outperform from Top Pick at RBC Capital... Best Buy (BBY) downgraded to Underperform from Buy at BofA/Merrill... Cablevision (CVC) downgraded to Hold from Buy at Jefferies... Credit Suisse (CS) downgraded to Hold from Buy at Deutsche Bank... Domino's Pizza (DPZ) downgraded to Sector Weight from Overweight at KeyBanc... First Quantum Minerals (FQVLF) downgraded to Neutral from Outperform at Credit Suisse... First Republic (FRC) downgraded to Market Perform from Outperform at FBR Capital... Fresenius SE (FSNUY) downgraded to Neutral from Buy at Goldman... Golden Minerals (AUMN) downgraded to Neutral from Buy at Roth Capital... JD Wetherspoon (JDWPY) downgraded to Reduce from Neutral at Nomura... NV5 Holdings (NVEE) downgraded to Neutral from Accumulate at Global Hunter... National Oilwell (NOV) downgraded to Sell from Neutral at UBS... Natural Gas Services (NGS) downgraded to Neutral from Buy at Global Hunter... Primoris (PRIM) downgraded to Neutral from Accumulate at Global Hunter... Receptos (RCPT) downgraded to Hold from Buy at Evercore ISI... SKF AB (SKFRY) downgraded to Hold from Buy at Deutsche Bank... STAG Industrial (STAG) downgraded to Sell from Neutral at UBS... SolarWinds (SWI) downgraded to Hold from Buy at Deutsche Bank... Syntel (SYNT) downgraded to Market Perform from Outperform at William Blair... TECO Energy (TE) downgraded to Neutral from Buy at UBS... Tangoe (TNGO) downgraded to Underweight from Equal Weight at Barclays... Tegna (TGNA) downgraded to Hold from Buy at Evercore ISI.
09:44 EDTBBYBest Buy falls after downgrade, levels to watch
Shares are down over 5% to $33.08. At that price next support is at $32.56, a recent pivot low, and then at $31.78. Resistance is at $34.14. BofA/Merrill earlier downgraded the shares to Underperform and cut its price target to $32.
07:26 EDTBBYBofA/Merrill downgrades Best Buy two notches to Underperform
As previously reported, BofA/Merrill downgraded Best Buy to Underperform from Buy. The firm lowered estimates based on limited catalysts and continued investments and warned that a mixed product cycle could result in 2H comp downside. BofA/Merrill believes the consensus estimate of 1% comps for 2H look challenging given ongoing computer weakness, ongoing tablet commodization and pricing pressure and flat mobile trends. The firm cut its price target on Best Buy to $32 from $45.
07:07 EDTBBYBest Buy downgraded to Underperform from Buy at BofA/Merrill

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use